AbbVie Inc (NYSE:ABBV) Beats Q2 2025 Earnings and Revenue Estimates, Raises Full-Year Guidance

AbbVie Inc (NYSE:ABBV) reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. The company’s performance reflects strength across its diversified portfolio, prompting an upward revision of its full-year outlook. The market reaction has been positive, with shares rising in pre-market trading.

Key Financial Highlights

• Revenue: AbbVie reported Q2 2025 revenue of $15.42 billion, surpassing the consensus estimate of $15.33 billion.
• Earnings Per Share (EPS): Adjusted diluted EPS came in at $2.97, beating expectations of $2.94 and marking a 12.1% increase year-over-year.
• GAAP vs. Adjusted EPS: On a GAAP basis, diluted EPS was $0.52, down 32.5% from the prior year, reflecting one-time charges or adjustments that impacted profitability.

Market Reaction

The stock is up 4.59% in pre-market trading, signaling investor optimism following the earnings beat. Despite a slight decline over the past month (-0.36%), the immediate positive reaction suggests confidence in AbbVie’s growth trajectory.

Outlook vs. Analyst Estimates

AbbVie raised its full-year guidance, citing strong momentum across its business segments. Analysts had projected full-year 2025 revenue at $61.11 billion and adjusted EPS at $12.39. The company’s upward revision aligns with these expectations, reinforcing its ability to sustain growth.

For Q3 2025, analysts estimate revenue of $15.75 billion and adjusted EPS of $3.31. AbbVie’s performance in the second quarter suggests it is well-positioned to meet or exceed these targets.

Press Release Takeaways

• Pipeline Progress: AbbVie highlighted regulatory approvals and promising clinical data, indicating continued innovation in immunology, oncology, and neuroscience.
• Diversified Growth: The company emphasized strength across its product portfolio, including key drugs like Skyrizi, Rinvoq, and Botox Therapeutic.
• Strategic Investments: Management pointed to external innovation investments as a driver of long-term growth.

For a deeper dive into AbbVie’s earnings and future estimates, visit the earnings estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.